Phase 2 N=20 Diagnostic

Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid

Eyelid Sebaceous Gland Carcinoma

Bottom Line

View on ClinicalTrials.gov: NCT00832429 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2025

Primary outcome: Primary: Sentinel Lymph Node Positivity — 2 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Lymph Node Mapping (Procedure); Sentinel Lymph Node Biopsy (Procedure); Technetium Tc-99m Sulfur Colloid (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: M.D. Anderson Cancer Center
Primary completion: Aug 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Sentinel Lymph Node Positivity	2	—

Summary

This phase II trial studies how well lymph node mapping works in finding disease that has spread from the place where it started to other places in the body in patients with sebaceous gland cancer of the eyelid. Lymph node mapping may help in planning surgery to remove cancer and affected lymph nodes.

Eligibility Criteria

Inclusion Criteria

Possible or suspicious sebaceous gland carcinoma of the eyelid
A CXR (chest x-ray), liver enzymes, and a head and neck computed tomography (CT), a single photon emission computed tomography (SPECT/CT) or magnetic resonance imaging (MRI) and an ultrasound negative for clinical evidence of metastasis
Patient provided written informed consent; in the event that non-English speaking participants are eligible for this study, a short form (if applicable) or an informed consent document (ICD) in their language, will be utilized and completed in accordance with the M.D. Anderson Cancer Center (MDACC) Policy for Consenting Non-English Speaking Participants

Exclusion Criteria

Pregnant or nursing females

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00832429). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.